Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Urologie
Erschienen in: Der Urologe 11/2016

19.10.2016 | Benigne Prostatahyperplasie | Leitthema

Minimal-invasive Therapie des benignen Prostatasyndroms

verfasst von: G. Magistro, C. G. Stief, C. Gratzke

Erschienen in: Die Urologie | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Entwicklung neuer minimal-invasiver Methoden zur Behandlung des benignen Prostatasyndroms (BPS) hat zum Ziel, ein günstigeres Sicherheitsprofil bei gleichwertiger Effizienz im Vergleich zu den Referenzverfahren zu erreichen. Dabei werden zusätzliche Aspekte wie der Erhalt der sexuellen Funktion inklusive antegrader Ejakulation berücksichtigt. Idealerweise wird im ambulanten Setting nur unter lokaler Betäubung operiert, um die Rekonvaleszenzzeit möglichst kurz zu halten. Die intraprostatischen Injektionstherapien (Botulinum-Neurotoxin A, NX-1207, PRX302) haben bislang in Phase-III-Studien die initial vielversprechenden Ergebnisse nicht bestätigt. Mechanische Verfahren wie Urolift® haben sich bereits in der kurz- und mittelfristigen klinischen Evaluierung bewährt und dabei Vorteile gegenüber etablierten Techniken, v. a. im Erhalt der antegraden Ejakulation, aufgezeigt. Weitere innovative Technologien wie die Aquablation (AquaBeam®) sind in der Entwicklung, jedoch steht eine endgültige klinisch Bewertung hinsichtlich Durchführbarkeit, Wirksamkeit und Sicherheit aus.
Literatur
1.
Vuichoud C, Loughlin KR (2015) Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol 22(Suppl 1):1–6PubMed
2.
Taub DA, Wei JT (2006) The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep 7(4):272–281PubMedCrossRef
3.
Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM (2008) The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol 53(4):819–825 (discussion 25–7)PubMedCrossRef
4.
Parsons JK, Wilt TJ, Wang PY, Barrett-Connor E, Bauer DC, Marshall LM et al (2010) Progression of lower urinary tract symptoms in older men: a community based study. J Urol 183(5):1915–1920PubMedPubMedCentralCrossRef
5.
Roehrborn CG (2008) BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 101(Suppl 3):17–21PubMedCrossRef
6.
Berges RR, Pientka L (1999) Management of the BPH syndrome in Germany: Who is treated and how? Eur Urol 36(Suppl 3):21–27PubMedCrossRef
7.
Boeing H, Wahrendorf J, Becker N (1999) EPIC-German y – a source for studies into diet and risk of chronic diseases. European investigation into cancer and nutrition. Ann Nutr Metab 43(4):195–204PubMedCrossRef
8.
Riboli E, Kaaks R (1997) The EPIC Project: rationale and study design. European prospective investigation into cancer and nutrition. Int J Epidemiol 26(Suppl 1):S6–S14PubMedCrossRef
9.
10.
Agarwal A, Eryuzlu LN, Cartwright R, Thorlund K, Tammela TL, Guyatt GH et al (2014) What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol 65(6):1211–1217PubMedPubMedCentralCrossRef
11.
AWMF (2014) Reg.-Nr:043-035: S2e Leitlinie – Therapie des Benignen Prostatasyndroms (BPS)
12.
13.
Roehrborn CG et al (2003) American Urological Association guideline: management of benign prostatic hyperplasia (BPH). American Urological Association, Linthicum
14.
McVary KT, Avins AL, Bruskewitz RC (2010) American Urological Association guideline: management of benign prostatic hyperplasia (BPH). American Urological Association, Linthicum
15.
Lu-Yao GL, Barry MJ, Chang CH, Wasson JH, Wennberg JE (1994) Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 44(5):692–698 (discussion 8–9)PubMedCrossRef
16.
McConnell JD (1994) Benign prostatic hyperplasia. J Urol 152(2 Pt 1):459–460PubMed
17.
18.
Grise P, Plante M, Palmer J, Martinez-Sagarra J, Hernandez C, Schettini M et al (2004) Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 46(4):496–501 (discussion 502)PubMedCrossRef
19.
Plante MK, Folsom JB, Zvara P (2004) Prostatic tissue ablation by injection: a literature review. J Urol 172(1):20–26PubMedCrossRef
20.
Andersson KE (2013) Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol 47(2):83–90PubMedCrossRef
21.
Magistro G, Stief CG, Gratzke C (2015) New intraprostatic injectables and prostatic urethral lift for male LUTS. Nat Rev Urol 12(8):461–471PubMedCrossRef
22.
Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB (2004) Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 64(5):871–875 (discussion 5)PubMedCrossRef
23.
Aoki KR (2005) Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26(5):785–793PubMedCrossRef
24.
Chuang YC, Chancellor MB (2006) The application of botulinum toxin in the prostate. J Urol 176(6 Pt 1):2375–2382PubMedCrossRef
25.
Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB (2004) Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172(4 Pt 1):1529–1532PubMedCrossRef
26.
De Biasi S, Rustioni A (1988) Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord. Proc Natl Acad Sci USA 85(20):7820–7824PubMedPubMedCentralCrossRef
27.
Dray A, Urban L, Dickenson A (1994) Pharmacology of chronic pain. Trends Pharmacol Sci 15(6):190–197PubMedCrossRef
28.
Duggan MJ, Quinn CP, Chaddock JA, Purkiss JR, Alexander FC, Doward S et al (2002) Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 277(38):34846–34852PubMedCrossRef
29.
MacKenzie I, Burnstock G, Dolly JO (1982) The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomic neuromuscular transmission. Neuroscience 7(4):997–1006PubMedCrossRef
30.
Rapp DE, Turk KW, Bales GT, Cook SP (2006) Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175(3 Pt 1):1138–1142PubMedCrossRef
31.
Smith CP, Chancellor MB (2004) Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 171(6 Pt 1):2128–2137PubMedCrossRef
32.
Smith CP, Franks ME, McNeil BK, Ghosh R, de Groat WC, Chancellor MB et al (2003) Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol 169(5):1896–1900PubMedCrossRef
33.
Arnouk R, Suzuki Bellucci CH, Benatuil Stull R, de Bessa J Jr., Malave CA, Mendes Gomes C (2012) Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. ScientificWorldJournal 2012:463574PubMedPubMedCentralCrossRef
34.
Chuang YC, Chiang PH, Yoshimura N, De Miguel F, Chancellor MB (2006) Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98(5):1033–1037 (discussion 337)PubMedCrossRef
35.
Crawford ED, Hirst K, Kusek JW, Donnell RF, Kaplan SA, McVary KT et al (2011) Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol 186(3):965–970PubMedPubMedCentralCrossRef
36.
Hamidi Madani A, Enshaei A, Heidarzadeh A, Mokhtari G, Farzan A, Mohiti Asli M et al (2013) Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol 31(1):235–239PubMedCrossRef
37.
Kuo HC, Liu HT (2009) Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scand J Urol Nephrol 43(3):206–211PubMedCrossRef
38.
Park DS, Cho TW, Lee YK, Lee YT, Hong YK, Jang WK (2006) Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 47(5):706–714PubMedPubMedCentralCrossRef
39.
Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G (2009) Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 73(1):90–94PubMedCrossRef
40.
Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB (2005) Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66(4):775–779PubMedCrossRef
41.
de Kort LM, Kok ET, Jonges TN, Rosier PF, Bosch JL (2012) Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia. Urology 80(4):889–893PubMedCrossRef
42.
Kuo HC (2005) Prostate botulinum A toxin injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65(4):670–674PubMedCrossRef
43.
Nikoobakht M, Daneshpajooh A, Ahmadi H, Namdari F, Rezaeidanesh M, Amini S et al (2010) Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport. Scand J Urol Nephrol 44(3):151–157PubMedCrossRef
44.
Sacco E, Bientinesi R, Marangi F, Totaro A, D’Addessi A, Racioppi M et al (2012) Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3‑month results of a prospective single-armed cohort study. BJU Int 110(11 Pt C):E837–E344PubMedCrossRef
45.
Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Oliveira R et al (2009) Intraprostatic Botulinum toxin type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol 9:9PubMedPubMedCentralCrossRef
46.
Silva J, Pinto R, Carvalho T, Botelho F, Silva P, Silva C et al (2011) Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 107(12):1950–1954PubMedCrossRef
47.
Silva J, Silva C, Saraiva L, Silva A, Pinto R, Dinis P et al (2008) Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 53(1):153–159PubMedCrossRef
48.
Yokoyama T, Yamamoto Y, Suzuki T, Oguma K, Nagai A (2012) Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin. Acta Med Okayama 66(4):291–297PubMed
49.
Marberger M, Chartier-Kastler E, Egerdie B, Lee KS, Grosse J, Bugarin D et al (2013) A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol 63(3):496–503PubMedCrossRef
50.
Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62(2):259–264 (discussion 64–65)PubMedCrossRef
51.
McVary KT, Roehrborn CG, Chartier-Kastler E, Efros M, Bugarin D, Chen R et al (2014) A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 192(1):150–156PubMedCrossRef
52.
Chartier-Kastler E, Mehnert U, Denys P, Giuliano F (2011) Botulinum neurotoxin A for male lower urinary tract symptoms. Curr Opin Urol 21(1):13–21PubMedCrossRef
53.
Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A et al (2011) Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 60(4):784–795PubMedCrossRef
54.
Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C et al (2014) An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 65(5):981–990PubMedCrossRef
55.
Oeconomou A, Madersbacher H (2010) Botulinum neurotoxin A for benign prostatic hyperplasia. Curr Opin Urol 20(1):28–36PubMedCrossRef
56.
Oeconomou A, Madersbacher H, Kiss G, Berger TJ, Melekos M, Rehder P (2008) Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. Eur Urol 54(4):765–775PubMedCrossRef
57.
Shore N (2010) NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 19(2):305–310PubMedCrossRef
58.
59.
Buckley JT (1992) The channel-forming toxin aerolysin. FEMS Microbiol Immunol 5(1–3):13–17PubMedCrossRef
60.
Christensson A, Laurell CB, Lilja H (1990) Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194(3):755–763PubMedCrossRef
61.
Froehner M, Hakenberg OW, Koch R, Schmidt U, Meye A, Wirth MP (2006) Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Urol Int 76(1):27–30PubMedCrossRef
62.
Savblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H (2005) Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 65(1):66–72PubMedCrossRef
63.
Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R et al (2007) Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 18(7):809–816PubMedCrossRef
64.
Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR (2007) A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 99(5):376–385PubMedPubMedCentralCrossRef
65.
Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P (2011) Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 59(5):747–754PubMedCrossRef
66.
Gravas SBA, Descazeaud A, Drake M, Gratzke C, Madersbacher S et al (2015) EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)
67.
Woo HH, Chin PT, McNicholas TA, Gill HS, Plante MK, Bruskewitz RC et al (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108(1):82–88PubMedCrossRef
68.
Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE et al (2013) The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol 190(6):2161–2167PubMedCrossRef
69.
McVary KT, Gange SN, Shore ND, Bolton DM, Cowan BE, Brown BT et al (2014) Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med 11(1):279–287PubMedCrossRef
70.
Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL et al (2015) Three year results of the prostatic urethral L.I.F.T. study. Can J Urol 22(3):7772–7782PubMed
71.
Sonksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D et al (2015) Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol 68(4):643–652PubMedCrossRef
72.
Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE et al (2014) Multicentre prospective crossover study of the „prostatic urethral lift“ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int 113(4):615–622PubMedCrossRef
73.
Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ et al (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79(1):5–11PubMedCrossRef
74.
McNicholas TA, Woo HH, Chin PT, Bolton D, Fernandez Arjona M, Sievert KD et al (2013) Minimally invasive prostatic urethral lift: surgical technique and multinational experience. Eur Urol 64(2):292–299PubMedCrossRef
75.
Shore N, Freedman S, Gange S, Moseley W, Heron S, Tutrone R et al (2014) Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol 21(1):7094–7101PubMed
76.
Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P et al (2012) Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9(2):568–575PubMedCrossRef
77.
Perera M, Roberts MJ, Doi SA, Bolton D (2015) Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Urol 67(4):704–713PubMedCrossRef
78.
Faber K, de Abreu AL, Ramos P, Aljuri N, Mantri S, Gill I et al (2015) Image-guided robot-assisted prostate ablation using water jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol 29(1):63–69PubMedCrossRef
79.
Gilling P, Reuther R, Kahokehr A, Fraundorfer M (2016) Aquablation – image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int 117(6):923–929PubMedCrossRef
80.
Sturch P, Woo HH, McNicholas T, Muir G (2015) Ejaculatory dysfunction after treatment for lower urinary tract symptoms: retrograde ejaculation or retrograde thinking? BJU Int 115(2):186–187PubMedCrossRef
Metadaten
Titel
Minimal-invasive Therapie des benignen Prostatasyndroms
verfasst von
G. Magistro
C. G. Stief
C. Gratzke
Publikationsdatum
19.10.2016
Verlag
Springer Medizin
Erschienen in
Die Urologie / Ausgabe 11/2016
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI
https://doi.org/10.1007/s00120-016-0249-4

Weitere Artikel der Ausgabe 11/2016

Der Urologe 11/2016 Zur Ausgabe

GeSRU

1. Kölner OP-Workshop – Verbessere deine operativen Fähigkeiten!

CME

Therapie der Harnleiterobstruktion

URO-Telegramm

URO-Telegramm

Erratum

Erratum zu: Generation Y – Problem oder Lösung im klinischen Alltag?

Einführung zum Thema

Langzeitergebnisse nach instrumenteller Therapie des Benignen Prostata-Syndroms (BPS)

Übersichten

Sozialmedizinische Begutachtung bei Patienten mit Prostatakarzinom

Passend zum Thema

ANZEIGE
Phytotherapie bei CPPS

Pollstimol®: Leitliniengerechte Prostatitis-Therapie

In 90 % der Prostatitis-Fälle handelt es sich um eine chronische abakterielle Prostatitis (chronic pelvic pain syndrome, CPPS) mit anhaltender Entzündungsreaktion und Schwellung der Prostata. Als leitliniengerechte Behandlungsoption mit guter Evidenz hat sich das Phytotherapeutikum Pollstimol® etabliert.

Bildnachweise